Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T09005
(Former ID: TTDS00532)
|
|||||
| Target Name |
Corynebacterium Mutated CRM197 (Cory mTOX)
|
|||||
| Synonyms |
Diphtheria toxin; DIP0222
Click to Show/Hide
|
|||||
| Gene Name |
Cory mTOX
|
|||||
| Target Type |
Successful target
|
[1] | ||||
| Disease | [+] 2 Target-related Diseases | + | ||||
| 1 | Infectious meningitis [ICD-11: 1D01] | |||||
| 2 | Meningococcal disease [ICD-11: 1C1C] | |||||
| Function |
Contains a single base change in the structural gene resulting in the substitution of glutamic acid for glycine which blocks ADP-ribosylation.
Click to Show/Hide
|
|||||
| UniProt ID | ||||||
| EC Number |
EC 2.4.2.36
|
|||||
| Sequence |
MSRKLFASILIGALLGIGAPPSAHAGADDVVDSSKSFVMENFSSYHGTKPGYVDSIQKGI
QKPKSGTQGNYDDDWKGFYSTDNKYDAAGYSVDNENPLSGKAGGVVKVTYPGLTKVLALK VDNAETIKKELGLSLTEPLMEQVGTEEFIKRFGDGASRVVLSLPFAEGSSSVEYINNWEQ AKALSVELEINFETRGKRGQDAMYEYMAQACAGNRVRRSVGSSLSCINLDWDVIRDKTKT KIESLKEHGPIKNKMSESPNKTVSEEKAKQYLEEFHQTALEHPELSELKTVTGTNPVFAG ANYAAWAVNVAQVIDSETADNLEKTTAALSILPGIGSVMGIADGAVHHNTEEIVAQSIAL SSLMVAQAIPLVGELVDIGFAAYNFVESIINLFQVVHNSYNRPAYSPGHKTQPFLHDGYA VSWNTVEDSIIRTGFQGESGHDIKITAENTPLPIAGVLLPTIPGKLDVNKSKTHISVNGR KIRMRCRAIDGDVTFCRPKSPVYVGNGVHANLHVAFHRSSSEKIHSNEISSDSIGVLGYQ KTVDHTKVNSKLSLFFEIKS Click to Show/Hide
|
|||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Approved Drug(s) | [+] 2 Approved Drugs | + | ||||
| 1 | Meningococcal groups A, C, Y and W-135 conjugate vaccine | Drug Info | Approved | Meningococcal infection | [1] | |
| 2 | Pneumococcal 13-valent conjugate vaccine | Drug Info | Approved | Streptococcus infection | [1] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Binder | [+] 2 Binder drugs | + | ||||
| 1 | Meningococcal groups A, C, Y and W-135 conjugate vaccine | Drug Info | [1] | |||
| 2 | Pneumococcal 13-valent conjugate vaccine | Drug Info | [1] | |||
| Drug Binding Sites of Target | Top | |||||
|---|---|---|---|---|---|---|
| Ligand Name: Hydroxyacetone | Ligand Info | |||||
| Structure Description | Crystal structure of diphtheria toxin mutant CRM197 with a disulphide bond replaced by a Cys-Acetone-Cys bridge | PDB:7O4W | ||||
| Method | X-ray diffraction | Resolution | 2.03 Å | Mutation | Yes | [2] |
| PDB Sequence |
GADDVVDSSK
10 SFVMENFSSY20 HGTKPGYVDS30 IQKGIQKPKS40 GNYDDDWKEF53 YSTDNKYDAA 63 GYSVDNENPL73 SGKAGGVVKV83 TYPGLTKVLA93 LKVDNAETIK103 KELGLSLTEP 113 LMEQVGTEEF123 IKRFGDGASR133 VVLSLPFAEG143 SSSVEYINNW153 EQAKALSVEL 163 EINFETRGKR173 GQDAMYEYMA183 QACLSCINLD205 WDVIRDKTKT215 KIESLKEHGP 225 IKNKMSESPN235 KTVSEEKAKQ245 YLEEFHQTAL255 EHPELSELKT265 VTGTNPVFAG 275 ANYAAWAVNV285 AQVIDSETAD295 NLEKTTAALS305 ILPGIGSVMG315 IADGAVHHNT 325 EEIVAQSIAL335 SSLMVAQAIP345 LVGELVDIGF355 AAYNFVESII365 NLFQVVHNSY 375 NRPAYSPGHK385 TQPFLHDGYA395 VSWNTVEDSI405 IRTGFQGESG415 HDIKITAENT 425 PLPIAGVLLP435 TIPGKLDVNK445 SKTHISVNGR455 KIRMRCRAID465 GDVTFCRPKS 475 PVYVGNGVHA485 NLHVAFHRSS495 SEKIHSNEIS505 SDSIGVLGYQ515 KTVDHTKVNS 525 KLSLFFEIKS535
|
|||||
|
|
||||||
| Click to View More Binding Site Information of This Target with Different Ligands | ||||||
| Different Human System Profiles of Target | Top |
|---|---|
|
Human Similarity Proteins
of target is determined by comparing the sequence similarity of all human proteins with the target based on BLAST. The similarity proteins for a target are defined as the proteins with E-value < 0.005 and outside the protein families of the target.
A target that has fewer human similarity proteins outside its family is commonly regarded to possess a greater capacity to avoid undesired interactions and thus increase the possibility of finding successful drugs
(Brief Bioinform, 21: 649-662, 2020).
Human Similarity Proteins
|
|
|
There is no similarity protein (E value < 0.005) for this target
|
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5. | |||||
| REF 2 | Retaining the structural integrity of disulfide bonds in diphtheria toxoid carrier protein is crucial for the effectiveness of glycoconjugate vaccine candidates. Chem Sci. 2022 Feb 10;13(8):2440-2449. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.